EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Key signalling pathways in head and neck squamous cell carcinoma: mechanisms and therapeutic targets

Enas Bani-Ahmad, Joshua Dass, Crispin R Dass

Journal of Pharmacy and Pharmacology · 2026-01-16 · 78 (1)

DOI: 10.1093/jpp/rgaf093 ↗
AbstractBibliografische Angaben

Abstract

Abstract Objectives This review examines the signalling pathways involved in head and neck cancer cell survival and apoptosis. Methods Articles were sourced from Scopus using the following keywords: oral cavity cancer, head and neck squamous cell carcinoma, signalling pathways, target therapy. No publication date limits were set, and the language of publication was restricted to English. Key findings Head and neck cancers are the sixth most common cancer worldwide (head and neck squamous cell carcinoma [HNSCC]). The most common subtype is squamous cell carcinoma (SCC), with oral and oropharyngeal squamous cell carcinoma (OSCC and OPSCC, respectively) being significant subcategories. Multiple signalling pathways play a critical role in oncogenesis and the development of various head and neck malignancies. Theoretically, targeting inhibitors for these pathways could potentially halt tumour growth and restore affected cells. This review highlights key oncogenic cascades, including epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT/mTOR, mitogen-activated protein kinase/extracellular signal-regulated kinase, Wnt/β-catenin, NOTCH, the p53 gene, and vascular endothelial growth factor, which contribute to tumour progression, invasion, and therapeutic resistance. A comprehensive understanding of these molecular mechanisms is essential to inform targeted therapies and develop personalized treatment strategies for HNSCC. Conclusions Researchers have studied several signalling pathways in HNSCC due to their known ability to influence apoptosis, survival, angiogenesis, and other biological processes.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →